Drugs Made In America Acquisition Corp (DMAA) FinancialsDMAADrugs Made In America Acquisition Corp

Evaluating the bottom line, Drugs Made In America Acquisition Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.33%, provide a clear picture of how effectively DMAA converts its operational activities into shareholder value.

In the context of the broader market, DMAA competes directly with industry leaders such as FACT and TRGS. With a market capitalization of $261.22M, it holds a leading position in the sector. When comparing efficiency, DMAA's gross margin of N/A stands against FACT's N/A and TRGS's N/A. Such benchmarking helps identify whether Drugs Made In America Acquisition Corp is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating net income, with Q2 2026 net income at 1,726,897 USD, but the overall trend is inconsistent, especially with a significant drop in Q4 2025.